Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma

Study on Plasmablastic Lymphoma Patients

NCT06781359 ·Status: RECRUITING

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

NCT07126236 ·Status: RECRUITING ·Phase: PHASE2

Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

NCT01361191 ·Status: COMPLETED ·Phase: PHASE2

Impact of Lymphodepletion Regimen on the Response to CAR T-cells in Patients With With Relapsed/Refractory Large B-cell Lymphoma

NCT06988085 ·Status: NOT_YET_RECRUITING

Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL

NCT04697160 ·Status: COMPLETED

Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma

NCT06822829 ·Status: RECRUITING

PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors

NCT05078840 ·Status: RECRUITING

Indolent Non Follicular Lymphomas Prognostic Project

NCT02904577 ·Status: COMPLETED

Prospective Observational Study of Diffuse Large-cell B Lymphoma

NCT06241729 ·Status: RECRUITING

Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)

NCT03104478 ·Status: COMPLETED

Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

NCT04300101 ·Status: RECRUITING

Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

NCT01466868 ·Status: TERMINATED ·Phase: PHASE2

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

NCT00169130 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

NCT05459571 ·Status: COMPLETED ·Phase: PHASE2

Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma

NCT04183569 ·Status: UNKNOWN

A Retrospective Study on Extranodal DLBCL

NCT06549361 ·Status: COMPLETED

Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma

NCT02474550 ·Status: UNKNOWN

Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

NCT04433182 ·Status: TERMINATED ·Phase: PHASE2

An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma

NCT01724294 ·Status: TERMINATED

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT01197560 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program

NCT06782789 ·Status: RECRUITING

Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.

NCT07181785 ·Status: COMPLETED

Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

NCT05958134 ·Status: COMPLETED

Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line

NCT01127841 ·Status: UNKNOWN ·Phase: PHASE2

Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT

NCT01523834 ·Status: COMPLETED ·Phase: PHASE2